Skip to main content
SpringerLink
Log in

Cytogenetics of Myeloproliferative Disorders

  • Conference paper
Molecular Basis of Chronic Myeloproliferative Disorders

  • 77 Accesses

Abstract

Unlike the Philadelphia chromosome in chronic myeloid leukemia (CML), there is no pathognomonic chromosomal abnormality associated with the cMPDs. However, a number of recurrent chromosomal abnormalities have been documented. Chromosomal abnormalities, as detected by G-banding, are seen in 30-40 % of patients with polycythemia vera (PV) and idiopathic myelofibrosis (IMF) (Table4.1) but are infrequent in patients with essential thrombocythemia (ET).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Swolin B, Weinfeld A, Westin J (1988) A prospective long-term cytogenetic study in polycythemia vera in relation to treatment and clinical course. Blood 72:386–395

    PubMed  CAS  Google Scholar 

  2. Diez-Martin JL, Graham DL, Petitt RM, Dewald GW (1991) Chromosome studies in 104 patients with polycythemia vera. Mayo Clinic Proc 66:287–299

    Article  CAS  Google Scholar 

  3. Bench AJ, Nacheva EP, Champion KM, Green AR (1998) Molecular genetics and cytogenetics of myeloproliferative disorders. In: Green AR, Pearson TC (eds) Myeloproliferative disorders. Baillière Tindall, London, pp 819–848

    Google Scholar 

  4. Rege-Cambrin G, Mecucci C, Tricot G, Michaux J-L, Louwagie A, Van Hove W, Francart H, Van den Bergh H (1987) A chromosomal profile of polycythemia vera. Cancer Genet Cytogenet 25:233–245

    Article  PubMed  CAS  Google Scholar 

  5. Reilly JT, Snowden JA, Spearing RL, Fitzgerald PM, Jones N, Watmore A, Potter A (1997) Cytogenetic abnormalities and their prognostic significance in idiopathic myelofibrosis: a study of 106 cases. Br J Haematol 98:96–102

    Article  PubMed  CAS  Google Scholar 

  6. Dewald GW, Schad CR, Lilla VC, Jalal SM (1993) Frequency and photographs of HGM11 chromosome anomalies in bone marrow samples from 3,996 patients with malignant hematologic neoplasms. Cancer Genet Cytogenet 68:60–69

    Article  PubMed  CAS  Google Scholar 

  7. Campbell LJ, Garson OM (1994) The prognostic significance of deletion of the long arm of chromosome 20 in myeloid disorders. Leukemia 8:67–71

    PubMed  CAS  Google Scholar 

  8. White NJ, Nacheva E, Asimakopoulos FA, Bloxham D, Paul B, Green AR (1994) Deletion of chromosome 20q in myelodysplasia can occur in a multipotent precursor of both myeloid cells and B cells. Blood 83:2809–2816

    PubMed  CAS  Google Scholar 

  9. Hollings PE, Rosman I, Beard MEJ (1994) A 20q deletion originating in a pluripotent stem cell. Blood 83:305–306

    PubMed  CAS  Google Scholar 

  10. Asimakopoulos FA, Holloway TL, Nacheva EP, Scott MA, Fenaux P, Green AR (1996) Detection of chromosome 20q deletions in bone marrow metaphases but not peripheral blood granulocytes in patients with myeloproliferative disorders or myelodysplastic syndromes. Blood 87:1561–1570

    PubMed  CAS  Google Scholar 

  11. Champion KM, Gilbert JG, Asimakopoulos FA, Hinshelwood S, Green AR (1997) Clonal haemopoiesis in normal elderly women: implications for the myeloproliferative disorders and myelodysplastic syndromes. Br J Haematol 97:920–926

    Article  PubMed  CAS  Google Scholar 

  12. Wang PW, Iannantuoni K, Davis EM, Espinosa III R, Stoffel M, Le Beau MM (1998) Refinement of the common deleted segment in myeloid leukemias with a del(20q). Genes Chromosomes Cancer 21:75–81

    Article  PubMed  CAS  Google Scholar 

  13. Bench AJ, Nacheva EP, Hood TL, Holden JL, French L, Swanton S, Champion KM, Li J, Whittaker P, Stavrides G, Hunt AR, Huntly BJ, Campbell LJ, Bentley DR, Deloukas P, Green AR (2000) Chromosome 20 deletions in myeloid malignancies: reduction of the common deleted region, generation of a PAC/BAC contig and identification of candidate genes. Oncogene 19:3902–3913

    Article  PubMed  CAS  Google Scholar 

  14. Li J, Bench AJ, Vassiliou GS, Fourouclas N, Ferguson-Smith AC, Green AR (2004) Imprinting of the human L3MBTL gene, a polycomb family member located in a region of chromosome 20 deleted in human myeloid malignancies. Proc Natl Acad Sci U S A 101:7341–7346

    Article  PubMed  CAS  Google Scholar 

  15. Asimakopoulos FA, Holloway TL, Nacheva EP, Scott MA, Fenaux P, Green AR (1996) Deletion constitutes the major mechanism for loss of heterozygosity on chromosome 20q in polycythemia vera. Blood 88:2690–2698

    PubMed  CAS  Google Scholar 

  16. Gribble SM, Reid AG, Bench AJ, Huntly BJP, Grace C, Green AR, Nacheva EP (2003) Molecular cytogenetics of polycythaemia vera: lack of occult rearrangements detectable by 20q LSP screening, CGH, and M-FISH. Leukemia 17:1419–1421

    Article  PubMed  CAS  Google Scholar 

  17. Asimakopoulos FA, Green AR (1996) Deletions of chromosome 20q and the pathogenesis of myeloproliferative disorders. Br J Haematol 95:219–226

    Article  PubMed  CAS  Google Scholar 

  18. Pastore C, Nomdedeu J, Volpe G, Guerrasio A, Cambrin GR, Parvis G, Pautasso M, Daglio C, Mazza U, Saglio G, Gaidano G (1995) Genetic analysis of chromosome 13 deletions in BCR/ABL negative chronic myeloproliferative disorders. Genes Chromosomes Cancer 14:106–111

    Article  PubMed  CAS  Google Scholar 

  19. Najfeld V, Montella L, Scalise A, Fruchtman S (2002) Exploring polycythaemia vera with fluorescence in situ hybridization: additional cryptic 9p is the most frequent abnormality detected. Br J Haematol 119:558–566

    Article  PubMed  Google Scholar 

  20. Sinclair EJ, Forrest EC, Reilly JT, Watmore AE, Potter AM (2001) Fluorescence in situ hybridization analysis of 25 cases of idiopathic myelofibrosis and two cases of secondary myelofibrosis: monoallelic loss of RBI, D13S319 and D13S25 loci associated with cytogenetic deletion and translocation involving 13ql4. Br J Haematol 113:365–368

    Article  PubMed  CAS  Google Scholar 

  21. La Starza R, Wlodarska I, Aventin A, Falzetti D, Crescenzi B, Martelli MF, Van den Berghe H, Mecucci C (1998) Molecular delineation of 13q deletion boundaries in 20 patients with myeloid malignancies. Blood 91:231–237

    PubMed  Google Scholar 

  22. Mertens D, Wolf S, Schroeter P, Schaffner C, Dohner H, Stilgenbauer S, Lichter P (2002) Down-regulation of candidate tumor suppressor genes within chromosome band 13ql4.3 is independent of the DNA methylation pattern in B-cell chronic lymphocytic leukaemia. Blood 99:4116–4121

    Article  PubMed  CAS  Google Scholar 

  23. Migliazza A, Bosch F, Komatsu H, Cayanis E, Martinotti S, Toniato E, Guccione E, Qu X, Chien M, Murty VV, Gaidano G, Inghirami G, Zhang P, Fischer S, Kalachikov SM, Russo J, Edelman I, Efstratiadis A, Dalla-Favera R (2001) Nucleotide sequence, transcription map, and mutation analysis of the 13ql4 chromosomal region deleted in B-cell chronic lymphocytic leukaemia. Blood 97:2098–2140

    Article  PubMed  CAS  Google Scholar 

  24. Cook WD, McCaw BJ (2000) Accommodating haploinsufficient tumor suppressor genes in Knudson’s model. Oncogene 19:3434–3438

    Article  PubMed  CAS  Google Scholar 

  25. Bench AJ, Aldred MA, Humphray SJ, Champion KM, Gilbert JGR, Asimakopoulos FA, Deloukas P, Gwilliam R, Bentley DR, Green AR (1998) A detailed physical and transcriptional map of the region of chromosome 20 that is deleted in myeloproliferative disorders and refinement of the common deleted region. Genomics 49:351–362

    Article  PubMed  CAS  Google Scholar 

  26. Jenkins RB, Le Beau MM, Kraker WJ, Borell TJ, Stalboerger PG, Davis EM, Penland L, Fernald A, Esponosa R III, Schaid DJ, Noel P, Dewald GW (1992) Fluorescence in situ hybridization: a sensitive method for trisomy 8 detection in bone marrow specimens. Blood 79:3307–3315

    PubMed  CAS  Google Scholar 

  27. Arranz E, Robledo M, Martinez B, Prieto E, Portero JA, Benitez J (1997) Detection of trisomy 8 using conventional cytogenetic techniques and interphase FISH analysis in 34 myeloid disorders: a comparative study. Cancer Genet Cytogenet 94:103–105

    Article  PubMed  CAS  Google Scholar 

  28. Westwood NB, Gruszka-Westwood AM, Pearson CE, DeLord CFM, Green AR, Huntly BJP, Lakhani A, McMullin MF, Pearson TC (2000) The incidences of trisomy 8, trisomy 9 and D20S108 deletion in polycythaemia vera: an analysis of blood granulocytes using interphase fluorescence in situ hybridization. Br J Haematol 110:839–846

    Article  PubMed  CAS  Google Scholar 

  29. Price CM, Kanfer EJ, Colman SM, Westwood N, Barrett AJ, Greaves MF (1992) Simultaneous genotypic and immunophenotypic analysis of interphase cells using dual-colour fluorescence: a demonstration of lineage involvement in polycythemia vera. Blood 80:1033–1038

    PubMed  CAS  Google Scholar 

  30. Rege-Cambrin G, Speleman F, Kerim S, Scaravaglio P, Carozzi F, Dal Cin P, Michaux J-L, Offner F, Saglio G, Van Den Berghe H (1991) Extra translocation +der(lq9p) is a prognostic indicator in myeloproliferative disorders. Leukemia 5:1059–1063

    PubMed  CAS  Google Scholar 

  31. Swolin B, Weinfeld A, Westin J (1986) Trisomy lq in polycythemia vera and its relation to disease transition. Am J Hematol 22:155–167

    Article  PubMed  CAS  Google Scholar 

  32. Fonatsch C, Haase D, Freund M, Bartels H, Tesch H (1991) A nonrandom primary chromosomal abnormality in myelodysplastic syndromes? Cancer Genet Cytogenet 56:243–253

    Article  PubMed  CAS  Google Scholar 

  33. Knuutila S, Ruutu T, Partanen S, Vuopio P (1983) Chromosome lq+ in erythroid and granulocytemonocyte precursors in a patient with essential thrombocythemia. Cancer Genet Cytogenet 9:245–249

    Article  PubMed  CAS  Google Scholar 

  34. Bench AJ, Cross NCP, Huntly BJP, Nacheva EP, Green AR (2001) Myeloproliferative disorders. In: Buckle V, Kearney L (eds) Cytogenetics in haematology. Best Practice and Research Clinical Haematology. Baillière Tindall, London, vol 14, pp 531–551

    Google Scholar 

  35. Inhorn RC, Aster JC, Roach SA, Slapak CA, Soiffer R, Tantravahi R, Stone RM (1995) A syndrome of lymphoblastic lymphoma, eosinophilia, and myeloid hyperplasia/malignancy associated with t(8;13)(p11;q11): description of a distinctive clinicopathologic entity. Blood 85:1881–1887

    PubMed  CAS  Google Scholar 

  36. Macdonald D, Reiter A, Cross NC (2002) The 8pll myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1. Acta Haematol 107:101–107

    Article  PubMed  CAS  Google Scholar 

  37. Xiao S, McCarthy JG, Aster JC, Fletcher JA (2000) ZNF198-FGFR1 transforming activity depends on a novel proline-rich ZNF198 oligomerization domain. Blood 96:699–704

    PubMed  CAS  Google Scholar 

  38. Golub TR, Barker GF, Lovett M, Gilliland DG (1994) Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 77:307–316

    Article  PubMed  CAS  Google Scholar 

  39. McWhirter JR, Galasso DL, Wang YL (1993) A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. Mol Cell Biol 13:7587–7595

    PubMed  CAS  Google Scholar 

  40. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, Kutok J, Clark J, Galinsky I, Griffin JD, Cross NC, Tefferi A, Malone J, Alam R, Schrier SL, Schmid J, Rose M, Van den Berghe P, Verhoef G, Boogaerts M, Wlodarska I, Kantarjian H, Marynen P, Coutre SE, Stone R, Gilliland DG (2003) A tyrosine kinase created by fusion of the PDGFRA and FIP 1 L 1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348:1201–1214

    Article  PubMed  CAS  Google Scholar 

  41. Pardanani A, Ketterling RP, Brockman SR, Flynn HC, Paternoster SF, Shearer BM, Reeder TL, Li CY, Cross NC, Cools J, Gilliland DG, Dewald GW, Tefferi A (2003) CHId 2 deletion, a surrogate for FIP 1 L 1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 102:3093–3096

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Haematology, Cambridge Institute for Medical Research, Addenbrooke’s Hospital, University of Cambridge, Hills Road, Cambridge, CB2 2XY, UK

    Anthony J. Bench

Authors
  1. Anthony J. Bench
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Brian J. Petro Huntly
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anthony R. Green
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Hematology Oncology Center, Zweibrückenstr. 2, 80331, Munich, Germany

    Petro E. Petrides M.D., Ph.D.

  2. University of Munich Medical School, Munich, Germany

    Petro E. Petrides M.D., Ph.D.

  3. Department of Experimental Anaesthesiology, University Hospital Freiburg, Center for Clinical Research, Breisacher Strasse 66, 79106, Freiburg, Germany

    Heike L. Pahl Ph.D.

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Bench, A.J., Huntly, B.J.P., Green, A.R. (2004). Cytogenetics of Myeloproliferative Disorders. In: Petrides, P.E., Pahl, H.L. (eds) Molecular Basis of Chronic Myeloproliferative Disorders. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-18738-4_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-18738-4_4

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-62271-7

  • Online ISBN: 978-3-642-18738-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation